Arcturus Therapeutics to Present at Guggenheim Securities SMID Cap Biotech Conference
Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company ...
Arcturus Therapeutics (NASDAQ:ARCT) Now Covered by Analysts at BTIG Research
BTIG Research began coverage on shares of Arcturus Therapeutics (NASDAQ:ARCT – Get Free Report) in a research report issued on Tuesday, MarketBeat reports. The brokerage set a “buy” rating and a ...
H.C. Wainwright Keeps Their Hold Rating on Durect (DRRX)
H.C. Wainwright analyst Ed Arce maintained a Hold rating on Durect (DRRX – Research Report) today. The company’s shares opened today at ...
Arcturus Therapeutics' SWOT analysis: mRNA innovator's stock faces pivotal year
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT), a commercial-stage biotechnology company with a market capitalization of ...
Fintel on MSN1d
BTIG Initiates Coverage of Arcturus Therapeutics Holdings (ARCT) with Buy Recommendation
Fintel reports that on January 28, 2025, BTIG initiated coverage of Arcturus Therapeutics Holdings (NasdaqGM:ARCT) with a Buy ...
Arcturus: Downgrading As mRNA Promise Meets Market Reality
Arcturus Therapeutics Holdings Inc. stock is down 46% since Sept. 2023 coverage; mRNA sector faces headwinds with public ...
Demystifying Arcturus Therapeutics: Insights From 5 Analyst Reviews
In the assessment of 12-month price targets, analysts unveil insights for Arcturus Therapeutics, presenting an average target ...
Arcturus Therapeutics initiated with a Buy at BTIG
BTIG initiated coverage of Arcturus Therapeutics (ARCT) with a Buy rating and $41 price target Arcturus is a commercial-stage biotechnology ...
Leerink Partnrs Has Bullish Outlook for ARCT FY2024 Earnings
Equities research analysts at Leerink Partnrs upped their FY2024 EPS estimates for shares of Arcturus Therapeutics in a note ...